The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases

This week, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases. In the area of business, Hansoh Pharmaceutical Group introduced EGFR/cMet bispecific antibodies, which are expected to link up with Almonertinib in a deal valued at up to RMB1.468 billion. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business. You can get more industry insights and firsthand market information from China to the globe at  PharmaSources.com

 

The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. All you need to do is getting it registered now and activate your complimentary pass to CPHI & PMEC China Online VEC Event,  and access your personal dashboard to connect with potential partners and new suppliers, arrange video meetings, and reserve your spot at expert-led content sessions. Hope you enjoy your VEC journey. Learn more about the event and get your free pass here: CPHI & PMEC China Virtual Expo Connect (pharmasources.com)